Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OLARATUMAB Cause Product use in unapproved indication? 40 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 40 reports of Product use in unapproved indication have been filed in association with OLARATUMAB. This represents 7.1% of all adverse event reports for OLARATUMAB.

40
Reports of Product use in unapproved indication with OLARATUMAB
7.1%
of all OLARATUMAB reports
7
Deaths
14
Hospitalizations

How Dangerous Is Product use in unapproved indication From OLARATUMAB?

Of the 40 reports, 7 (17.5%) resulted in death, 14 (35.0%) required hospitalization, and 17 (42.5%) were considered life-threatening.

Is Product use in unapproved indication Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OLARATUMAB. However, 40 reports have been filed with the FAERS database.

What Other Side Effects Does OLARATUMAB Cause?

Off label use (124) Neutropenia (66) Infusion related reaction (64) Febrile neutropenia (57) Drug ineffective (49) Death (44) Malignant neoplasm progression (43) Disease progression (33) Anaphylactic reaction (29) Dyspnoea (27)

What Other Drugs Cause Product use in unapproved indication?

DUPILUMAB (33,452) DICLOFENAC (12,197) METHOTREXATE (8,930) PREDNISONE (7,625) RITUXIMAB (7,519) MYCOPHENOLATE MOFETIL (5,910) ACETAMINOPHEN (5,819) CYCLOPHOSPHAMIDE (5,750) RISPERIDONE (5,551) TACROLIMUS (5,057)

Which OLARATUMAB Alternatives Have Lower Product use in unapproved indication Risk?

OLARATUMAB vs OLECLUMAB OLARATUMAB vs OLIVE OIL\SOYBEAN OIL OLARATUMAB vs OLMESARTAN OLARATUMAB vs OLMESARTAN MEDOXOMIL OLARATUMAB vs OLMETEC

Related Pages

OLARATUMAB Full Profile All Product use in unapproved indication Reports All Drugs Causing Product use in unapproved indication OLARATUMAB Demographics